外泌体miRNA在甲状腺癌淋巴结转移临床诊断中的研究进展

doi:10.11904/j.issn.1002-3070.2023.05.008

摘要/Abstract

摘要： 甲状腺癌是一种惰性肿瘤,患者发生淋巴结转移(Lymph node metastasis,LNM)的比例较高,且转移后患者复发率高,临床预后较差。解决这一问题的关键在于寻找具有高特异性的无创生物标志物。外泌体通过传递遗传物质,在细胞通讯及表观遗传调控中扮演着至关重要的角色。甲状腺肿瘤细胞可以通过外泌体中的miRNA将遗传信息转移到肿瘤微环境中,将周围的微环境改变为一个适合肿瘤生长的环境,从而促进甲状腺肿瘤的增殖和迁移。本文将对近年外泌体miRNA在甲状腺癌转移的早期诊断中发挥的作用及其应用前景进行阐述,为探寻甲状腺癌生物标志物提供参考依据。

关键词: 甲状腺癌, 外泌体, 生物标志物

Abstract: Thyroid cancer(TC)is an inert tumor,with a high proportion of patients undergoing lymph node metastasis(LNM),and a high recurrence rate after metastasis,resulting in a poor clinical prognosis.The key to solving this problem is to find non-invasive biomarkers with high specificity.Extracellular vesicles play a crucial role in intercellular communication and epigenetic regulation by transporting genetic material.TC tumor cells can transfer genetic information to the tumor microenvironment through miRNA in exosomes,changing the surrounding microenvironment into an environment suitable for tumor growth,thereby promoting proliferation and migration of TC.This article will review the role and application prospects of extracellular miRNAs in the early diagnosis of TC metastasis in recent years,to provide a reference for exploring biomarkers of TC.

Key words: Thyroid cancer, Exosomes, Biomarkers

中图分类号:

R736.1

曹文源, 罗晓婷, 何倩. 外泌体miRNA在甲状腺癌淋巴结转移临床诊断中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 434-438.

CAO Wenyuan, LUO Xiaoting, HE Qian. Research progress of exosomal miRNA in Clinical diagnosis of lymph node metastasis in thyroid cancer[J]. Journal of Practical Oncology, 2023, 37(5): 434-438.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.05.008

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I5/434

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
3 Asimakopoulos P,Shaha AR,Nixon IJ,et al.Management of the neck in well-differentiated thyroid cancer[J].Current Oncology Reports,2020,23(1):1.
4 Yu J,Deng Y,Liu T,et al.Lymph node metastasis prediction of papillary thyroid carcinoma based on transfer learning radiomics[J].Nat Commun,2020,11(1):4807.
5 Xu SW,Mo CQ,Lin JY,et al.Loss of ID3 drives papillary thyroid cancer metastasis by targeting E47-mediated epithelial to mesenchymal transition[J].Cell Death Discov,2021,7(1):226.
6 Kim DH,Kim GJ,Kim SW,et al.Predictive value of ipsilateral central lymph node metastasis for contralateral central lymph node metastasis in patients with thyroid cancer:systematic review and meta-analysis[J].Head Neck,2021,43(10):3177-3184.
7 Feng J W,Qu Z,Ye J,et al.Nomograms to predict ipsilateral and contralateral central lymph node metastasis in clinically lymph node-negative patients with solitary isthmic classic papillary thyroid carcinoma[J].Surgery,2021,170(6):1670-1679.
8 Guo JN,Song LH,Yu PY,et al.Ultrasound elastic parameters predict central lymph node metastasis of papillary thyroid carcinoma[J].J Surg Res,2020,253:69-78.
9 李卓林,贾如雪,吴亚婷,等.肿瘤转移的分子机制及靶向干预研究新进展[J].中华细胞与干细胞杂志,2022,12(1):51-58.
10 Zhang L,Yu D.Exosomes in cancer development,metastasis,and immunity[J].Biochim Biophys Acta Rev Cancer,2019,1871(2):455-468.
11 Kandoth C,Michael D,Vandin F,et al.Mutational landscape and significance across 12 major cancer types[J].Nature,2013,502(7471):333-339.
12 W Yu,J Hurley,D Roberts,et al.Exosome-based liquid biopsies in cancer:opportunities and challenges[J].Ann Oncol,2021,32(4):466-477.
13 Kalluri R,LeBleu VS.The biology,function,and biomedical applications of exosomes[J].Science,2020,367(6478):6977.
14 Agarwal K,Saji M,Lazaroff SM,et al.Analysis of exosome release as a cellular response to MAPK pathway inhibition[J].Langmuir,2015,31(19):5440-5448.
15 Xing MZ.Molecular pathogenesis and mechanisms of thyroid cancer[J].Nat Rev Cancer,2013,13(3):184-199.
16 Sun Z,Shi K,Yang S,et al.Effect of exosomal miRNA on cancer biology and clinical applications[J].Mol Cancer,2018,17(1):147.
17 Lai EC.Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation[J].Nat Genet,2002,30(4):363-364.
18 Bracken CP,Scott HS,Goodall GJ.A network-biology perspective of microRNA function and dysfunction in cancer[J].Nat Rev Genet,2016,17(12):719-732.
19 Mehta A,Baltimore D.MicroRNAs as regulatory elements in immune system logic[J].Nat Rev Immunol,2016,16(5):279-294.
20 Silaghi CA,Lozovanu V,Silaghi H,et al.The prognostic value of microRNAs in thyroid cancers-a systematic review and meta-analysis[J].Cancers(Basel),2020,12(9):2608.
21 Stewart LA,Kuo JH.Advancements in the treatment of differentiated thyroid cancer[J].Ther Adv Endocrinol Metab,2021,12:20420188211000251.
22 Toraih EA,Elshazli RM,Trinh LN,et al.Diagnostic and prognostic performance of liquid biopsy-derived exosomal microRNAs in thyroid cancer patients:a systematic review and meta-analysis[J].Cancers(Basel),2021,13(17):4295.
23 Toraih EA,Fawzy MS,Hussein MH,et al.MicroRNA-based risk score for predic-42ting tumor progression following radioactive iodine ablation in well-differentiated thyroid cancer patients:a propensity-score matched analysis[J].Cancers(Basel),2021,13(18):4649.
24 Chan SH,Wang LH.Regulation of cancer metastasis by microRNAs[J].J Biomed Sci,2015,22(1):9.
25 Orellana EA,Kasinski AL.MicroRNAs in cancer:a historical perspective on the path from discovery to therapy[J].Cancers(Basel),2015,7(3):1388-1405.
26 Wang XZ,Hang YK,Liu JB,et al.Over-expression of microRNA-375 inhibits papillary thyroid carcinoma cell proliferation and induces cell apoptosis by targeting ERBB2[J].J Pharmacol Sci,2016,130(2)78-84.
27 Min L,Zhu S,Chen L,et al.Evaluation of circulating small extracellular vesicles derived miRNAs as biomarkers of early colon cancer:a comparison with plasma total miRNAs[J].J Extracell Vesicles,2019,8(1):1643670.
28 Zhu Lei,Li Jiao,Gong YL,et al.Exosomal tRNA-derived small RNA as a promising biomarker for cancer diagnosis[J].Mol Cancer,2019,18(1):74.
29 Peng Y,Li C,Luo DC,et al.Expression profile and clinical significance of microRNAs in papillary thyroid carcinoma[J].Molecules,2014,19(8):11586-11599.
30 Pallante P,Visone R,Ferracin M,et al.MicroRNA deregulation in human thyroid papillary carcinomas[J].Endocrine-Related Cancer,2006,13(2):497508.
31 Zhiyun Wei,Arsen O Batagov,Sergio Schinelli,et al.Coding and noncoding landscape of extracellular RNA released by human glioma stem cells[J].Nat Commun,2017,8(1):1145.
32 Laura Santangelo,Giorgio Giurato,Carla Cicchini,et al.The RNA-binding protein syncrip is a component of the hepatocyte exosomal machinery controlling MicroRNA sorting[J].Cell Rep,2016,17(3):799-808.
33 Chen WJ,Li GP,Li ZH,et al.Evaluation of plasma exosomal miRNAs as potential diagnostic biomarkers of lymph node metastasis in papillary thyroid carcinoma[J].Endocrine,2022,75(3):846-855.
34 Niu MY,Li H,Li X,et al.Circulating exosomal mirnas as novel biomarkers perform superior diagnostic efficiency compared with plasma mirnas for large-artery atherosclerosis stroke[J].Front Pharmacol,2021,26(12):791644.
35 Pan Q,Zhao J,Li M,et al.Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing[J].Carcinogenesis,2020,41(1):18-24.
36 Batagov AO,Kurochkin IV.Exosomes secreted by human cells transport largely mRNA fragments that are enriched in the 3'-untranslated regions[J].Biology Direct,2013,8(1):12.
37 Villarroya-Beltri C,Gutiérrez-Vázquez C,Sánchez-Cabo F,et al.Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs[J].Nat Commun,2013,4:2830.
38 Santangelo L,Giurato G,Cicchini C,et al.The RNA-binding protein syncrip is a component of the hepatocyte exosomal machinery controlling MicroRNA sorting[J].Cell Rep,2016,17(3):799-808.
39 Kim S,Choi MC,Jeong JY,et al.Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas[J].J Cancer,2019,10(9):1958-1967.
40 Yue S,Ye X,Zhou T,et al.PGRN(-/-)TAMs-de-rived exosomes inhibit breast cancer cell invasion and migration and its mechanism exploration[J].Life Sci,2021,264:118687.
41 Dai DF,Tan YW,Guo LF,et al.Identification of exosomal miRNA biomarkers for diagnosis of papillary thyroid cancer by small RNA sequencing[J].Eur J Endocrinol,2020,182(1):111-121.
43 叶卫东,邓先兆,樊友本.外泌体miRNA146b-5p促进甲状腺乳头状癌细胞迁移和侵袭[J].外科理论与实践,2019,24(4):344-348.
44 Chen WJ,Li GP,Li ZH,et al.Evaluation of plasma exosomal miRNAs as potential diagnostic biomarkers of lymph node metastasis in papillary thyroid carcinoma[J].Endocrine,2022,75(3):846-855.
45 Ye W,Deng X,Fan Y.Exosomal miRNA423-5p mediated oncogene activity in papillary thyroid carcinoma:a potential diagnostic and biological target for cancer therapy[J].Neoplasma,2019,66(4):516-523.
46 Jiang K,Li GP,Chen WJ,et al.Plasma exosomal miR-146b-5p and miR-222-3p are potential biomarkers for lymph node metastasis in papillary thyroid carcinomas[J].Onco Targets Ther,2020,13:1311-1319.
47 Capriglione F,Verrienti A,Celano M,et al.Analysis of serum microRNA in exosomal vehicles of papillary thyroid cancer[J].Endocrine,2022,75(1):185-193.
48 Deng X,Wu B,Xiao K,et al.MiR-146b-5p promotes metastasis and induces epithelial-mesenchymal transition in thyroid cancer by targeting ZNRF3[J].Cell Physiol Biochem,2015,35(1):71-82.
49 Huang Y,Yu S,Cao S,et al.MicroRNA-222 promotes invasion and metastasis of papillary thyroid cancer through targeting protein phosphatase 2 regulatory subunit B alpha expression[J].Thyroid,2018,28(9):1162-1173.
50 Xiang D,Tian B,Yang T,et al.miR-222 expression is correlated with the ATA risk stratifications in papillary thyroid carcinomas[J].Medicine(Baltimore),2019,98(25):e16050.

[1]	鲁亚杰, 王丽红. 蒽环类药物相关心脏毒性早期生物标志物研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 496-501.
[2]	王利, 王科进. 骨髓微环境在白血病发病机制中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 524-528.
[3]	赵诗璐, 庞达. 乳腺癌预后相关基因的生物信息学筛选与分析[J]. 实用肿瘤学杂志, 2023, 37(5): 422-428.
[4]	马晶昱, 相智声, 林永添, 温烨莹, 周衍. 2011—2020年福建省肿瘤登记地区甲状腺癌流行特征及变化趋势[J]. 实用肿瘤学杂志, 2023, 37(4): 301-307.
[5]	高哲敏, 李晓雪, 霍恺, 王立彬, 陈静, 鲁文慧. 沧州市区2010—2019年甲状腺癌发病时间趋势和生存分析[J]. 实用肿瘤学杂志, 2023, 37(3): 195-199.
[6]	张慧, 闫旺, 孙明华. 奇异南星挥发油通过miR-762/NF2轴对甲状腺癌细胞恶性生物学行为的影响[J]. 实用肿瘤学杂志, 2023, 37(3): 207-214.
[7]	吴南楠, 尹瑞梨, 孙荣欣, 赵冬. 基于生物信息学方法分析FAM20A在甲状腺癌中的诊断价值[J]. 实用肿瘤学杂志, 2023, 37(3): 230-235.
[8]	周兴安, 苏尼特, 武旭, 达林泰, 德乐黑巴特尔. 外泌体lncRNA在鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(2): 160-163.
[9]	余银平, 蔺嘉楠, 王立中, 蒋威华. 癌源性外泌体对乳腺癌MCF-7细胞生物学行为的影响[J]. 实用肿瘤学杂志, 2023, 37(1): 26-31.
[10]	鲁姣阳, 常进. 多发性骨髓瘤生物标志物研究进展[J]. 实用肿瘤学杂志, 2023, 37(1): 87-91.
[11]	李浩, 滕立臣. 外泌体环状RNA在前列腺癌中的研究现状[J]. 实用肿瘤学杂志, 2023, 37(1): 92-96.
[12]	岳杰, 杨麒麟, 孙翔宇, 孙誉铭, 麻响, 陈东, 静广平. 牙髓干细胞外泌体对口腔鳞状细胞癌CAL-27增殖、迁移的影响及其机制的研究[J]. 实用肿瘤学杂志, 2022, 36(5): 398-403.
[13]	赵盛雯, 吴桐. ¹³¹I联合甲磺酸阿帕替尼治疗分化型甲状腺癌肺转移的短期疗效及安全性研究[J]. 实用肿瘤学杂志, 2022, 36(4): 323-326.
[14]	刘佳, 杨道坤, 王燕平, 陈宝鑫, 王新伟, 申娇. PD-1抑制剂治疗肝细胞癌疗效相关生物标志物的研究现状[J]. 实用肿瘤学杂志, 2022, 36(4): 374-380.
[15]	陈函, 罗晓勇, 李朝萍, 郭彩茹, 鞠文翠, 翟秧秧, 师鑫鹏. lncRNA CASC2对结直肠癌细胞功能及血管生成的影响[J]. 实用肿瘤学杂志, 2022, 36(2): 111-118.